Adani Group Disputes Regulatory Oversight at Airport Duty-Free Shops

The Adani Group is contesting the applicability of the Drugs and Cosmetics Act to its duty-free outlets, amid allegations of unauthorized nicotine pouch sales.

MUMBAI — The Adani Group, which manages the Chhatrapati Shivaji Maharaj International Airport in Mumbai, has formally argued that the Drugs and Cosmetics Act, 1940, should not apply to duty-free shops operating within international airport terminals. The position follows allegations from regulatory authorities that the airport’s duty-free outlets sold nicotine pouches in contravention of existing Indian laws.

The dispute highlights a growing friction between airport operators and health regulators regarding the jurisdiction and compliance requirements for retail establishments located in "international" zones. Documents reviewed by authorities suggest that the disagreement centers on whether the legislative framework governing drug sales in India extends to the tax-exempt, transit-restricted areas where international travelers shop.

The Regulatory Conflict

The controversy stems from an official investigation into the sale of nicotine pouches—a product often regulated as a drug or tobacco-related item—at Mumbai International Airport. Authorities have alleged that these products were sold without adhering to the stringent licensing and quality standards mandated by the Drugs and Cosmetics Act.

In response to these findings, the Adani Group has presented a legal argument maintaining that duty-free areas function under distinct regulatory exemptions. According to internal documents, the group asserts that the nature of these transit-restricted zones, which cater primarily to international passengers, necessitates a nuanced interpretation of domestic health regulations. The company suggests that applying the Drugs and Cosmetics Act to such areas could create jurisdictional overlap and operational difficulties for retail partners operating under international customs norms.

Implications for Airport Retail

The stance taken by the Adani Group poses significant questions for the broader airport retail industry. Duty-free shops have historically enjoyed a degree of administrative autonomy, often regulated more closely by Customs authorities than by local health departments. However, health officials argue that the sale of products containing nicotine or other potentially harmful substances must remain subject to national health standards, regardless of the retail location's geographic designation.

The outcome of this dispute could have lasting effects on the inventory and operational policies of airport retailers across India. If the government determines that the Drugs and Cosmetics Act—or similar public health legislation—applies to these zones, retailers may face mandatory product recalls, stricter licensing audits, and significant adjustments to their luxury and lifestyle product lines.

Official Sources

The concerns regarding regulatory compliance were raised in official reports and correspondence between health agencies and airport management. While the Adani Group has emphasized the distinct nature of its international terminals, the regulator remains firm in its mandate to enforce health standards across all commercial establishments operating within the country.

Quote Section

According to officials familiar with the inquiry, the central dispute revolves around the "territoriality of health laws" and whether the airport’s international status offers a legal shield against domestic pharmaceutical regulations. The Adani Group has maintained that its operations at the Mumbai terminal comply with all relevant international and customs-based frameworks applicable to duty-free retail.

Why It Matters

The practical implications of this dispute are twofold:

• For Consumers: Passengers may see changes in the availability of certain health or wellness products sold in duty-free zones if regulators enforce stricter compliance.

• For Businesses: Airport operators and retail partners may be forced to navigate a more complex web of dual-regulations, potentially impacting profitability and supply chain logistics for high-margin items like health-supplements and specialized tobacco alternatives.

Key Facts at a Glance

• Core Issue: Legal applicability of the Drugs and Cosmetics Act to duty-free shops in international transit zones.

• Allegation: Sale of nicotine pouches without compliance with national health and safety standards.

• Adani Group Position: Duty-free zones operate under specific customs exemptions that should preclude local pharmaceutical regulation.

• Regulatory Stance: Public health laws, including the Drugs and Cosmetics Act, remain supreme across all commercial retail spaces within national borders.

Frequently Asked Questions

Are nicotine pouches generally regulated in India? Yes, nicotine-related products often fall under various health and tobacco-control legislations, which require strict adherence to labeling and manufacturing standards.

Why is the Adani Group arguing against the application of the Drugs and Cosmetics Act? The group argues that the specific legal and customs framework governing international duty-free shops is distinct from general domestic commerce, implying that existing health-related acts were not intended for these transit-restricted zones.

Could this affect other products? If the regulator succeeds in applying the Act to these shops, it could potentially impact a wide range of goods—including supplements, cosmetics, and certain wellness items—that currently bypass standard domestic regulatory clearances.

Source: Mumbai International Airport Limited (MIAL) Filings, Drugs and Cosmetics Act, 1940 (Ministry of Health and Family Welfare), Adani One Terms of Service